Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency
Study Identifier:
LAL-CL06
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Sebelipase Alfa
Date
Jun 2014 - Dec 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 8+ years
Requirements Information
Sex
Female & Male
Age
8+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Sebelipase Alfa
Date
Jun 2014 - Dec 2017
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 8+ years years
Requirements Information
Protocol Summary
This study evaluated the safety and efficacy of sebelipase alfa in a broad population of participants with lysosomal acid lipase deficiency (LAL-D).
Trial Locations
Location
Status
Location
Chicago, Illinois, United States, 60611
Status
N/A
Location
Shreveport, Louisiana, United States, 71103
Status
N/A
Location
Cincinnati, Ohio, United States, 45229
Status
N/A
Location
Westmead, Australia, NSW 2145
Status
N/A
Location
Brussels, Belgium, 1200
Status
N/A
Location
Sao Paulo, Brazil, 04024-002
Status
N/A